Form 4: Omega Therapeutics Director Rainer J. Boehm Reports Stock Option Grant

Director Rainer J. Boehm reports the acquisition of stock options in Omega Therapeutics, Inc.

Summary

• Rainer J. Boehm, a director of Omega Therapeutics, Inc., filed a Form 4 with the SEC.
• The report details the grant of stock options to Boehm on June 20, 2024.
• Boehm acquired options to purchase 25,000 shares of Omega Therapeutics common stock at an exercise price of $2.20 per share.
• The options vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, contingent upon continued service on the Board of Directors.
• Following the transaction, Boehm directly owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (25,000 shares) would need to be compared to grants made to directors at comparable companies to assess its relative magnitude.
• Companies like Moderna, BioNTech, and CRISPR Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates

Keywords

Omega Therapeutics, Stock Options, Form 4, Director, Beneficial Ownership, OMGA, Rainer J. Boehm